Literature DB >> 1603095

Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP).

Y Reiter1, Z Fishelson.   

Abstract

The effect of sublytic doses of the complement membrane attack complexes (MAC) on protein synthesis in human leukemic cells was examined. As shown herein, rapid protein synthesis is evident in K562 erythroleukemic cells upon exposure to sublytic complement doses. Analysis of cell extracts by SDS-PAGE revealed high molecular weight proteins which appeared in the cells already after 15 min treatment with complement at 37 degrees C, reaching a maximal level after 40-50 min. These large complement-induced proteins (L-CIP) were clearly observed in gels stained by Coomassie blue and in autoradiograms following [35S]-Met or [3H]-Leu incorporation. Rabbit antibodies prepared against L-CIP were reactive in immunoassays with extracts of MAC-treated cells but not of non treated cells. They also bound to the surface of intact K562 cells (as determined by immunofluorescence), but only after treatment of the cells with complement. Both heterologous (rabbit and guinea pig) and homologous (human) sera induced L-CIP synthesis. The induction of L-CIP was indeed mediated by the complement MAC since L-CIP could not be detected in K562 cells exposed to heat-inactivated human serum or C6-deficient rabbit serum. Similarly, C7- or C8-deficient human sera could not induce L-CIP production unless they were reconstituted with purified human C7 or C8, respectively. The synthesis of L-CIP was largely inhibited by the protein synthesis inhibitors cycloheximide and puromycin and partially inhibited by the RNA synthesis inhibitor actinomycin D. L-CIP was similarly induced in two other human leukemic cell lines, U937 and HL-60, but not in K562/S, a subline of K562 which is highly sensitive to complement damage. These results are discussed with respect to the resistance of leukemic cells, and nucleated cells in general, to complement-mediated immune damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603095     DOI: 10.1016/0161-5890(92)90187-3

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis.

Authors:  S Kraus; R Seger; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

3.  Mechanisms of complement resistance induced by non-lethal complement attack and by growth arrest.

Authors:  K J Marchbank; C W van den Berg; B P Morgan
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 4.  Complement-related proteins in pathogenic organisms.

Authors:  Z Fishelson
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack.

Authors:  K J Marchbank; B P Morgan; C W van den Berg
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

Review 6.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

7.  SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.

Authors:  Ming-Bo Huang; Jennifer Y Wu; James Lillard; Vincent C Bond
Journal:  Oncotarget       Date:  2019-09-10

8.  Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.

Authors:  M Parizade; R Arnon; P J Lachmann; Z Fishelson
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.